ATX-101 (Deoxycholic Acid Injection) Treatment in Men: Insights From Our Clinical Experience
Sign Up to like & getrecommendations! Published in 2017 at "Dermatologic Surgery"
DOI: 10.1097/dss.0000000000001306
Abstract: BACKGROUND Excess submental fat (SMF), also called a double chin, is an area of concern for men that can be addressed clinically. ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada,… read more here.
Keywords: treatment; atx 101; deoxycholic acid; acid injection ... See more keywords
Reduction of Submental Fat Continues Beyond 28 Days After ATX-101 Treatment: Results From a Post hoc Analysis
Sign Up to like & getrecommendations! Published in 2018 at "Dermatologic Surgery"
DOI: 10.1097/dss.0000000000001484
Abstract: Injection of ATX-101 (deoxycholic acid injection) into subcutaneous fat results in adipocytolysis, which induces a predictable, localized inflammatory response to clear cellular debris and liberated lipids from the injection site. In the pivotal Phase 3… read more here.
Keywords: analysis; treatment; efficacy; atx 101 ... See more keywords
Real-World Experience With 100 Consecutive Patients Undergoing Neck Contouring With ATX-101 (Deoxycholic Acid): An Updated Report With A 2-Year Analysis
Sign Up to like & getrecommendations! Published in 2019 at "Dermatologic Surgery"
DOI: 10.1097/dss.0000000000001811
Abstract: BACKGROUND Deoxycholic acid (DCA; ATX-101) injection was approved for the treatment of mild-to-moderate convexity associated with submental fat in 2015. OBJECTIVE To evaluate the experience with DCA injections in a clinical practice setting. MATERIALS AND… read more here.
Keywords: consecutive patients; 100 consecutive; treatment; experience ... See more keywords
A Double-Blind, Placebo-Controlled, Phase 3b Study of ATX-101 for Reduction of Mild or Extreme Submental Fat.
Sign Up to like & getrecommendations! Published in 2019 at "Dermatologic Surgery"
DOI: 10.1097/dss.0000000000001850
Abstract: BACKGROUND ATX-101 (deoxycholic acid injection) is approved for reduction of moderate or severe submental fat (SMF). OBJECTIVE To evaluate the efficacy and safety of ATX-101 in subjects with mild or extreme SMF. PATIENTS AND METHODS… read more here.
Keywords: submental fat; smf; placebo; mild extreme ... See more keywords
ATX-101 (Deoxycholic Acid Injection) Leads to Clinically Meaningful Improvement in Submental Fat: Final Data From CONTOUR.
Sign Up to like & getrecommendations! Published in 2019 at "Dermatologic Surgery"
DOI: 10.1097/dss.0000000000002092
Abstract: BACKGROUND Submental fat (SMF) can negatively affect perceptions of health and attractiveness. The Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR) was designed to understand SMF treatment in clinical practice. OBJECTIVE To report efficacy,… read more here.
Keywords: submental fat; smf; 101 deoxycholic; treatment ... See more keywords
Submental Area Treatment with ATX-101: Relationship of Mechanism of Action, Tissue Response, and Efficacy
Sign Up to like & getrecommendations! Published in 2022 at "Plastic and Reconstructive Surgery - Global Open"
DOI: 10.1097/gox.0000000000004250
Abstract: Background: ATX-101 is an injectable, synthetically derived formulation of deoxycholic acid used for submental fat reduction. Methods: A narrative review of references relevant to the mechanism of action of ATX-101 and its relationship to efficacy… read more here.
Keywords: mechanism action; treatment; response; atx 101 ... See more keywords
Abstract 6174: ATX-101, a peptide drug targeting PCNA, enhances the effect of gemcitabine in liposarcoma and leiomyosarcoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6174
Abstract: Soft tissue sarcomas are heterogeneous mesenchymal neoplasms and account for 1% of all cancers in adults. Over 50 sarcomas subtypes have been classified and many have very limited treatment options which include surgery, chemotherapy and… read more here.
Keywords: cell; atx 101; gemcitabine; liposarcoma leiomyosarcoma ... See more keywords
Safety profile and disease stabilization in late stage, heavily pretreated, solid tumor patients in a first-in-human (FIH) study of ATX-101, a drug targeting proliferating cell nuclear antigen (PCNA).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3067
Abstract: 3067 Background: PCNA is a conserved scaffold protein orchestrating DNA replication, repair or bypass pathways as well as cellular signaling and apoptosis. More than 500 protein-PCNA interactions have been identified which are mediated via two… read more here.
Keywords: fih study; treatment; pcna; atx 101 ... See more keywords
ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14020289
Abstract: Simple Summary PCNA is an interesting target for cancertreatment due to its essential activities in DNA replication and repair and its recently discovered regulatory roles in cellular signaling. Here, we demonstrate that ATX-101, a peptide… read more here.
Keywords: cell; 101 peptide; antitumor; targeting pcna ... See more keywords